

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer
subject to Section 16. Form 4 or
Form 5 obligations may
continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
Myers Jason W.		Invitae Corp [NVTA]		<input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) President, Oncology	
(Last) (First) (Middle)		3. Date of Earliest Transaction (MM/DD/YYYY)			
C/O INVITAE CORPORATION, 1400 16TH STREET		10/2/2020			
(Street)		4. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)	
SAN FRANCISCO, CA 94103				<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/2/2020		A		1039227	A	(1)(2)	1039227	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.86	10/2/2020		A		278417		(3)	10/1/2028	Common Stock	278417	(1)(4)	278417	D	
Stock Option (right to buy)	\$3.77	10/2/2020		A		643839		(3)	12/16/2029	Common Stock	643839	(1)(5)	643839	D	

Explanation of Responses:

- Received pursuant to the Agreement and Plan of Merger and Plan of Reorganization, dated as of June 21, 2020, by and among the Issuer, Apollo Merger Sub A Inc., a wholly-owned, direct subsidiary of the Issuer ("Merger Sub A"), Apollo Merger Sub B LLC, a wholly-owned, direct subsidiary of the Issuer ("Merger Sub B"), ArcherDX, Inc. ("ArcherDX"), and Kyle Lefkoff, solely in his capacity as holders' representative, pursuant to which ArcherDX merged with and into Merger Sub A, with ArcherDX surviving the merger as a wholly-owned subsidiary of the Issuer and immediately after such merger, ArcherDX merged with and into Merger Sub B with Merger Sub B surviving the merger as a wholly-owned subsidiary of the Issuer.
- Received in exchange for 374,578 shares of ArcherDX common stock and 676,379 shares of ArcherDX preferred stock.
- Option is fully vested and exercisable.
- Received in exchange for an option to acquire 281,560 shares of ArcherDX common stock.
- Received in exchange for an option to acquire 651,107 shares of ArcherDX common stock.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Myers Jason W. C/O INVITAE CORPORATION 1400 16TH STREET SAN FRANCISCO, CA 94103	X			President, Oncology

Signatures

/s/ Jason W. Myers

10/5/2020

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.